SYNTHETIC BIOLOGICS INC (SYN) Stock Price, Quote, News and Overview
NYSEARCA:SYN - NYSE Arca - US87164U4094 - Common Stock - Currency: USD
SYN Quote, Performance and Key Statistics
1.02
+0.01 (+0.99%)
The current stock price of SYN is 1.02 USD. In the past month the price decreased by -25.55%. In the past year, price decreased by -76.54%.
SYN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.17 | 360.64B | ||
| AMGN | AMGEN INC | 15.63 | 166.32B | ||
| GILD | GILEAD SCIENCES INC | 24.08 | 138.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1660.86 | 123.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.63 | 77.97B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.11B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.04B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.58B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.58 | 20.59B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.73 | 15.99B |
Related stock screener links
About SYN
Company Profile
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 16 full-time employees. The firm is focused on the development of oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a sustained anti-tumor response by the patient’s immune system. Its lead candidates are: VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract, and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under current good manufacturing practice (cGMP) conditions and intended to treat both local GI and systemic diseases.
Company Info
SYNTHETIC BIOLOGICS INC
Suite 412, 155 Gibbs Street
Rockville MARYLAND 20850 US
CEO: Steven A. Shallcross
Employees: 16
Company Website: https://www.syntheticbiologics.com/
Phone: 17343327800.0
SYNTHETIC BIOLOGICS INC / SYN FAQ
What is the stock price of SYNTHETIC BIOLOGICS INC today?
The current stock price of SYN is 1.02 USD. The price increased by 0.99% in the last trading session.
What is the ticker symbol for SYNTHETIC BIOLOGICS INC stock?
The exchange symbol of SYNTHETIC BIOLOGICS INC is SYN and it is listed on the NYSE Arca exchange.
On which exchange is SYN stock listed?
SYN stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for SYNTHETIC BIOLOGICS INC stock?
6 analysts have analysed SYN and the average price target is 6.12 USD. This implies a price increase of 500% is expected in the next year compared to the current price of 1.02. Check the SYNTHETIC BIOLOGICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SYNTHETIC BIOLOGICS INC worth?
SYNTHETIC BIOLOGICS INC (SYN) has a market capitalization of 16.16M USD. This makes SYN a Nano Cap stock.
How many employees does SYNTHETIC BIOLOGICS INC have?
SYNTHETIC BIOLOGICS INC (SYN) currently has 16 employees.
What are the support and resistance levels for SYNTHETIC BIOLOGICS INC (SYN) stock?
SYNTHETIC BIOLOGICS INC (SYN) has a resistance level at 1.05. Check the full technical report for a detailed analysis of SYN support and resistance levels.
Should I buy SYNTHETIC BIOLOGICS INC (SYN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SYN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SYN, evaluating the profitability, health, valuation and growth aspects
- SYNTHETIC BIOLOGICS INC (SYN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SYNTHETIC BIOLOGICS INC (SYN) Sales and EPS estimates to see what analysts future expectations are.
- SYNTHETIC BIOLOGICS INC (SYN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SYNTHETIC BIOLOGICS INC (SYN) Insider and Institutional Ownership to learn about the owners and their transactions.
- SYNTHETIC BIOLOGICS INC (SYN) Stock Chart to make your own analysis
- SYNTHETIC BIOLOGICS INC (SYN) Latest news and press-releases to stay up to date.
Does SYNTHETIC BIOLOGICS INC (SYN) stock pay dividends?
SYN does not pay a dividend.
When does SYNTHETIC BIOLOGICS INC (SYN) report earnings?
SYNTHETIC BIOLOGICS INC (SYN) will report earnings on 2022-11-02, after the market close.
What is the Price/Earnings (PE) ratio of SYNTHETIC BIOLOGICS INC (SYN)?
SYNTHETIC BIOLOGICS INC (SYN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.21).
SYN Technical Analysis
SYN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SYN. SYN has a bad profitability rating. Also its financial health evaluation is rather negative.
SYN Financial Highlights
Over the last trailing twelve months SYN reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS increased by 71.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.59% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
SYN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to SYN. The Buy consensus is the average rating of analysts ratings from 6 analysts.